Morphic Holding, Inc. - Common Stock (NQ:MORF)

56.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Morphic Holding, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

October 09, 2023

From Morphic Therapeutic

Via GlobeNewswire

MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

September 29, 2023

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review ↗

September 29, 2023

But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.

Via Investor's Business Daily

Where Morphic Holding Stands With Analysts ↗

September 28, 2023

Via Benzinga

Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17

July 17, 2023

Via Investor Brand Network

Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5

June 05, 2023

Via Investor Brand Network

Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence

September 26, 2023

From Morphic Therapeutic

Via GlobeNewswire

Gold Moves Lower; TransCode Therapeutics Shares Surge ↗

September 25, 2023

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to...

Via Benzinga

Topics Stocks

Morphic Therapeutic's Stock Plunges On Monday - Here's Why? ↗

September 25, 2023

Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 25, 2023

Via Benzinga

Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10

May 10, 2023

Via Investor Brand Network

Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 25, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.

Via Benzinga

The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days ↗

September 25, 2023

The company is working on a treatment for ulcerative colitis. But competitive questions linger.

Via Investor's Business Daily

Nasdaq Turns Higher; SCYNEXIS Shares Plunge ↗

September 25, 2023

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500...

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗

September 25, 2023

Via Benzinga

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

September 22, 2023

From Morphic Therapeutic

Via GlobeNewswire

Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 22, 2023

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 22, 2023

Via Benzinga

Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

August 29, 2023

From Morphic Therapeutic

Via GlobeNewswire

Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 09, 2023

From Morphic Therapeutic

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023 ↗

August 09, 2023

Via Benzinga

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023

August 03, 2023

From Morphic Therapeutic

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

3 Stocks That Could Skyrocket by This Time Next Summer ↗

June 08, 2023

The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist.

Via InvestorPlace

Morphic to Present at the Jefferies Global Healthcare Conference

June 06, 2023

From Morphic Therapeutic

Via GlobeNewswire

Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference

May 12, 2023

From Morphic Therapeutic

Via GlobeNewswire

Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis

May 11, 2023

-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-

From Morphic Therapeutic

Via GlobeNewswire

Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 05, 2023

From Morphic Therapeutic

Via GlobeNewswire

More Than $47M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗

May 05, 2023

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering

May 03, 2023

From Morphic Therapeutic

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.